To include your compound in the COVID-19 Resource Center, submit it here.

Doubling up over heparin

Regado's data for reversible anticoagulant to avoid bleeding, ischemic events

Regado Biosciences Inc. thinks its two-part reversible anticoagulants - consisting of a therapeutic aptamer and a complementary inhibitory aptamer - can improve outcomes vs. heparin for acute coronary syndrome in the acute care setting. The company said Phase IIb data show its lead aptamer pair can avoid the bleeding or ischemic events that result from too much or too little anticoagulation.

Regado plans to move into Phase III testing next year in acute coronary syndrome (ACS) patients undergoing open heart surgery.

The lead program, REG1, consists of a therapeutic aptamer called pegnivacogin (RB006) and a control agent called anivamersin (RB007). The control aptamer has no pharmacologic activity other than to bind to and deactivate the therapeutic aptamer, so the

Read the full 1172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers